title: ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation.
abstract: OBJECTIVE
  The development of chemoradiation - the concurrent administration of chemotherapy and radiotherapy - has led to significant improvements in local tumor control and survival. However, it is limited by its high toxicity. In this study, we report the development of a novel NP (nanoparticle) therapeutic, ChemoRad NP, which can deliver biologically targeted chemoradiation.
  
  
  METHODS
  A biodegradable and biocompatible lipid-polymer hybrid NP that is capable of delivering both chemotherapy and radiotherapy was formulated.
  
  
  RESULTS
  Using docetaxel, indium(111) and yttrium(90) as model drugs, we demonstrated that the ChemoRad NP can encapsulate chemotherapeutics (up to 9% of NP weight) and radiotherapeutics (100 mCi of radioisotope per gram of NP) efficiently and deliver both effectively. Using prostate cancer as a disease model, we demonstrated the targeted delivery of ChemoRad NPs and the higher therapeutic efficacy of ChemoRad NPs.
  
  
  CONCLUSIONS
  We believe that the ChemoRad NP represents a new class of therapeutics that holds great potential to improve cancer treatment.
authors.affiliation: Laboratory of Nanomedicine & Biomaterials, Department of Anesthesia, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. ofarokhzad@partners.org
authors.forename: Andrew Z
authors.initials: AZ
authors.lastname: Wang
authors.forename: Kai
authors.initials: K
authors.lastname: Yuet
authors.forename: Liangfang
authors.initials: L
authors.lastname: Zhang
authors.forename: Frank X
authors.initials: FX
authors.lastname: Gu
authors.forename: Minh
authors.initials: M
authors.lastname: Huynh-Le
authors.forename: Aleksandar F
authors.initials: AF
authors.lastname: Radovic-Moreno
authors.forename: Philip W
authors.initials: PW
authors.lastname: Kantoff
authors.forename: Neil H
authors.initials: NH
authors.lastname: Bander
authors.forename: Robert
authors.initials: R
authors.lastname: Langer
authors.forename: Omid C
authors.initials: OC
authors.lastname: Farokhzad
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D003131:Combined Modality Therapy; D000077143:Docetaxel; D006801:Humans; D007205:Indium Radioisotopes / Q000008:administration & dosage* / Q000494:pharmacology; D008297:Male; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D043823:Taxoids / Q000008:administration & dosage* / Q000494:pharmacology; D015021:Yttrium Radioisotopes / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D007205:Indium Radioisotopes; D043823:Taxoids; D015021:Yttrium Radioisotopes; D000077143:Docetaxel
references.citation: Langmuir. 2005 Sep 13;21(19):8852-7
references.pmid: 16142970
references.citation: Cancer Res. 1996 May 1;56(9):2123-9
references.pmid: 8616860
references.citation: Expert Rev Anticancer Ther. 2006 Mar;6(3):445-61
references.pmid: 16503861
references.citation: Br J Cancer. 1991 Dec;64(6):1125-32
references.pmid: 1764376
references.citation: Lancet. 1987 Sep 12;2(8559):624-5
references.pmid: 2887906
references.citation: Cancer Res. 2006 Jul 1;66(13):6732-40
references.pmid: 16818648
references.citation: Nano Lett. 2009 May;9(5):1909-15
references.pmid: 19344179
references.citation: Pharm Res. 2005 Dec;22(12):2107-14
references.pmid: 16254763
references.citation: Semin Nucl Med. 1989 Jul;19(3):187-201
references.pmid: 2503873
references.citation: ChemMedChem. 2007 Sep;2(9):1268-71
references.pmid: 17600796
references.citation: Cancer Res. 2002 Jul 15;62(14):4029-33
references.pmid: 12124337
references.citation: ACS Nano. 2008 Aug;2(8):1696-702
references.pmid: 19206374
references.citation: Expert Opin Drug Deliv. 2008 Apr;5(4):371-83
references.pmid: 18426380
references.citation: J Control Release. 2000 Mar 1;65(1-2):271-84
references.pmid: 10699287
references.citation: Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6315-20
references.pmid: 16606824
references.citation: Angew Chem Int Ed Engl. 2006 Dec 11;45(48):8149-52
references.pmid: 17099918
references.citation: J Control Release. 2004 Mar 24;95(3):613-26
references.pmid: 15023471
references.citation: ChemMedChem. 2008 Sep;3(9):1311-5
references.pmid: 18613203
references.citation: Int J Pharm. 2007 Sep 5;342(1-2):208-14
references.pmid: 17560058
references.citation: Nano Lett. 2007 Oct;7(10):3065-70
references.pmid: 17854227
references.citation: Nat Clin Pract Oncol. 2007 Feb;4(2):86-100
references.pmid: 17259930
references.citation: Nat Protoc. 2006;1(1):314-7
references.pmid: 17406251
references.citation: Cancer Res. 2004 Nov 1;64(21):7668-72
references.pmid: 15520166
references.citation: Cancer Biother Radiopharm. 2003 Feb;18(1):99-107
references.pmid: 12667313